AMPERSAND CAPITAL PARTNERS
AMPERSAND CAPITAL PARTNERS is a Series C+ fund in global writing $25M–$50M checks into Healthcare, life-sciences, laboratory-products-and-services, contract-manufacturing, pharma-services and specialty-products.
- Stages
- Series C+
- Sectors
- Healthcare, life-sciences, laboratory-products-and-services, contract-manufacturing, pharma-services, specialty-products
- Check size
- $25M–$50M
- Invests in
- global
- Actively investing
- Yes
- Founded
- 1988
- Assets under management
- $3 billion
Thesis
Ampersand Capital Partners is a middle-market private equity firm founded in 1988, specializing in growth-oriented investments within the life sciences and healthcare sectors. They focus on companies providing essential 'picks and shovels' for medical and pharmaceutical innovation, including laboratory products and services, contract manufacturing, pharma services (CDMOs, CROs), and specialty healthcare products. Ampersand partners with visionary founders and management teams, employing a strategy of minority and majority equity investments to drive expansion through organic growth and acquisitions. The firm has a global geographic scope with offices in Boston, Amsterdam, and London. They target growth-stage companies with revenues between $10 million and $200 million and positive EBITDA. Ampersand manages approximately $3 billion in AUM and recently closed its twelfth fund, AMP-26, with $1.5 billion in commitments.
Common questions
Does AMPERSAND CAPITAL PARTNERS invest at the Series C+ stage?
Yes. AMPERSAND CAPITAL PARTNERS lists Series C+ among the stages it invests in.
What check size does AMPERSAND CAPITAL PARTNERS write?
AMPERSAND CAPITAL PARTNERS writes $25M–$50M checks.
Where does AMPERSAND CAPITAL PARTNERS invest?
AMPERSAND CAPITAL PARTNERS invests in global.